Non-Invasive Technology That Improves Cardiac Function after Experimental Myocardial Infarction: Whole Body Periodic Acceleration (pGz)

Arkady Uryash, Jorge Bassuk, Paul Kurlansky, Francisco Altamirano, Jose R. Lopez, Jose A. Adams

1 Division of Neonatology, Mount Sinai Medical Center, Miami Beach, FL, United States of America, 2 Columbia Heart Source, Columbia University College of Physicians and Surgeons, New York, NY, United States of America, 3 Departments of Molecular Bioscience, School of Veterinary Medicine, University of California Davis, Davis, CA, United States of America

☯ These authors contributed equally to this work.
† Deceased.
‡ These authors also contributed equally to this work.
* tony-adams@msmc.com

Abstract

Myocardial infarction (MI) may produce significant inflammatory changes and adverse ventricular remodeling leading to heart failure and premature death. Pharmacologic, stem cell transplantation, and exercise have not halted the inexorable rise in the prevalence and great economic costs of heart failure despite extensive investigations of such treatments. New therapeutic modalities are needed. Whole Body Periodic Acceleration (pGz) is a non-invasive technology that increases pulsatile shear stress to the endothelium thereby producing several beneficial cardiovascular effects as demonstrated in animal models, normal humans and patients with heart disease. pGz upregulates endothelial derived nitric oxide synthase (eNOS) and its phosphorylation (p-eNOS) to improve myocardial function in models of myocardial stunning and preconditioning. Here we test whether pGz applied chronically after focal myocardial infarction in rats improves functional outcomes from MI. Focal MI was produced by left coronary artery ligation. One day after ligation animals were randomized to receive daily treatments of pGz for four weeks (MI-pGz) or serve as controls (MI-CONT), with an additional group as non-infarction controls (Sham). Echocardiograms and invasive pressure volume loop analysis were carried out. Infarct transmurality, myocardial fibrosis, and markers of inflammatory and anti-inflammatory cytokines were determined along with protein analysis of eNOS, p-eNOS and inducible nitric oxide synthase (iNOS). At four weeks, survival was 80% in MI-pGz vs 50% in MI-CONT (p < 0.01). Ejection fraction and fractional shortening and invasive pressure volume relation indices of afterload and contractility were significantly better in MI-pGz. The latter where associated with decreased infarct transmurality and decreased fibrosis along with increased eNOS, p-eNOS. Additionally, MI-pGz had significantly lower levels of iNOS, inflammatory cytokines (IL-6, TNF-α), and higher level of anti-inflammatory cytokine (IL-10). pGz improved survival and contractile function.
performance, associated with improved myocardial remodeling. pGz may serve as a simple, safe, non-invasive therapeutic modality to improve myocardial function after MI.

Introduction

Myocardial Infarction (MI) and its associated functional derangements may lead to heart failure that affects 2–3% of the population in industrialized countries with a marked rise in those aged > 65 yr. A combined estimate of ~ 20 million people suffer from heart failure in Europe and the US and its prevalence is increasing. In the US alone direct medical costs approximate $25 billion dollars per year and expected to triple by 2030 [1–4].

Attempts to ameliorate myocardial dysfunction after MI, using pharmacologic, stem cell transplantation, and exercise have been widely explored in experimental and in clinical trials. The search for simple inexpensive therapeutic interventions continues. Whole Body Periodic Acceleration (pGz) is the repetitive, sinusoidal head-foot motion of the body provided by a motion platform. As the body accelerates and decelerates, low amplitude pulses are added to the circulation as a function of platform frequency thereby increasing pulsatile shear stress to the endothelium [5–8, 9]. pGz through its increase of pulsatile shear stress upregulates eNOS and increases its phosphorylation p-eNOS (Ser 1177) [10]. eNOS phosphorylation after pGz is responsible for shear stress dependent vasodilatation and subsequent increase nitric oxide (eNO) release into the circulation [9, 11–13]. pGz applied in a swine model of myocardial stunning induced by whole body ischemia reperfusion injury, acutely improves myocardial function due to increase eNO as well as other cardioprotective mediators [6, 8, 10, 14]. The purpose of this investigation was to test whether pGz applied chronically after focal myocardial infarction in rats would improve functional outcomes from MI.

Materials and Methods

Animals and Experimental Design

The experimental protocol No. 13-08-A-03 was approved by the Mount Sinai Medical Center Animal Care and Use Committee and conforms to the Guide for the Care and Use of Laboratory Animals published by the National Institutes of Health [NIH Publication No. 85-23, revised 1996]. Adult male Sprague-Dawley rats (300–350 g) were randomly assigned to (n = 60): 1) pGz started 24 hr after MI, 1 hr per day 5 days per week for four weeks (MI-pGz) (n = 20); 2) A control group (MI-CONT) animals were placed on the pGz platform starting at 24 hr after MI but the platform was not actuated (n = 20); 3) Sham group, animals where anesthetized but no MI was induced (Sham) (n = 10) (Fig. 1).

pGz Protocol

After experimental MI was induced by permanent ligation of the left coronary artery, the animals recovered for 24 hr. Awake animals were placed in a restraint for 1 hr/day 5 days per week for four weeks. Optimal pGz frequency of 360 cpm and peak acceleration amplitude of Gz ± 2.9 m/sec² in rats for increased release of eNO was utilized [10, 13]. pGz was administered at the same time of the day for the various study groups. Animals who did not receive pGz were placed in the same restraint for the same number of days as the experimental groups.
Animals were anesthetized with Ketamine/Xylazine (80/10 mg/kg IM) intubated and ventilated with O₂ using a small-animal ventilator (Kent Scientific Corporation, Torrington, CT). Body temperature was maintained at 37.5 ± 0.5°C with a heated operating platform. Cardiac electrical activity was monitored continuously with 3 lead electrocardiogram. The tail vein was catheterized for intravenous fluids and drug administration. Left thoracotomy was performed and a permanent ligature placed around left anterior coronary artery at the mid-level. The thorax was closed in layers with silk sutures. Animals were extubated and recovered in their cages maintaining a thermo-neutral environment and received analgesia [Buprenex (buprenorphine) 0.1 mg/kg] immediately after surgery and every 6 to 12 hr. based on pain assessment. Animals are monitored hourly or until upright and ambulating. Once ambulating animals are assessed for post procedural pain every 4 hr. for the initial 48 hr., thereafter once per day until completion of the protocol. A modified score sheet system based on post procedural pain assessment of behavior, physiological stress signs and respirations is used to tabulate assessments (S1 Table) [15–17].

Echocardiogram and Invasive Hemodynamic Measurements

Echocardiograms where performed post MI at 1, 3, and 4 weeks of pGz or Control using an HP Sonos 2000 ultrasound imaging system (Hewlett-Packard, Andover, MA USA) with a 7.5 mHz transthoracic transducer. 2D/M-Mode techniques were applied to assess functional changes. Echocardiograms were performed in long- and short-axis following myocardial infarction in close-chest sedated rats. The chest was shaved and covered with ultra sound gel in order to provide air-free insonation. The left ventricle (LV) was visualized by middle long and short axis images. Middle long and short axis views were taken from the right ventricular side in order to
depict the left ventricle at a lower sector-angle. By reducing insonation angle without reducing spatial resolution, the technique provided images with a 76 frame rate. Three cardiac cycles were acquired and averaged by software. The correct tracking of border zones was visually controlled and manually corrected. Ejection time was defined by Doppler-registered aortic valve opening and closure. Conventional measurements (LV diameters, anterior wall (AW) and posterior wall (PW) thickness and thickening) were obtained from grayscale M-mode tracings. LV end-systolic and end-diastolic volumes and LV ejection fraction (LVEF) were measured by Simpson’s method from two-dimensional parasternal long- and short-axis views [18–20].

After four weeks of pGz or Control the animals where anesthetized and catheterization was performed with a Millar Catheter SPR-869 (Millar Instruments, Houston TX, USA). The conductance catheter was calibrated by a cuvette calibration method using an actual blood sample in cuvette between 50 and 300 μl. In vivo the conductance signal was calibrated using hypertonic saline. An intravenous bolus of 50 μl of 20% saline was used to perform calibration. In order to decrease preload, a small abdominal incision was performed to localize and perform inferior vena cava (IVC) occlusions. PVL where continuously recorded at baseline, after saline infusion, and during and after IVC occlusions. Recording and calculations were performed using data acquisition software (LabChart7Pro, ADInstruments, Colorado Springs, CO).

Sham Surgery

Sham protocol was identical to MI experiments with the exception of coronary artery ligation. At the completion of the sham surgery, animals were recovered and allowed to remain in their cage with free access to chow and water for the remainder of their study time period.

Animals which met pre-established humane endpoints for euthanasia or completed the experimental protocol were euthanized by a dose of Ketamine 90mg/kg and Xylazine 25mg/kg, followed by pentobarbital 100mg/kg IP, until absence of corneal and pedal reflex, and no electrical activity on ECG, and decapitation via guillotine, a method approved by the American Veterinary Medical Association Guidelines on Euthanasia. Perfusion and or organ harvesting was performed as per protocol [21–24].

Detection and Assessment of Infarcted Area, Transmurality and Fibrosis

Validation of coronary occlusion was performed by our laboratory according to the procedure previously described [25]. In a separate cohort of animals (n = 10) infarct size was determined after 24 hr. of coronary occlusion to determine infarct size. At the end of the study (four weeks after ligation) and after all hemodynamic measurements, the aorta was clamped and the hearts were perfused with 10mL of saline through a cannula in the ascending aorta to wash out the blood from the myocardium [26]. After saline perfusion, Evans Blue (EB) was injected into the ascending aorta to separate the non-at-risk area from the risk area. The hearts were cut out and cut in 3, 3mm segments from apex to base parallel to the atrioventricular groove. The segments were incubated for 30 minutes in 2,3,5-triphenyltetrazolium chloride (TTC) at 37°C in the dark. The segments were fixed between two glass sheets and non-at-risk area, the area-at-risk and the necrotic area were determined by planimetry [27]. The basal side of the segments was measured to better distinguish between myocardium stained by EB and TTC. Segments for comparison were chosen on the basis of reproducibility of area-at-risk to perfused myocardium ratio between animals. Images of the segments were taken with a digital camera set to 60 x magnifications through a dissecting microscope (Olympus, Center Valley, PA). Viable myocardium (TTC red stained) and infarcted (TTC unstained) areas non-at-risk area (EB–blue stained) were measured using a computer program (Adobe Photoshop, Adobe Systems Incorporated, San Jose, CA). The percentage share of each the preceding areas was calculated.
Area at risk measured by the Evans Blue (EB) perfusion-staining and expressed as percent of whole heart. Necrosis was measured by TTC staining and expressed as percent of each myocardial segment. To determine transmurality of the infarct scanned images of the segments were geometrically divided into a 6-sector model using the anterior and inferior insertion of the right ventricle to the left ventricle as markers [28]. Apical, middle and basal necrosis was defined. The sectors were divided into the following groups on the background of the distribution of necrotic myocardium: transmural necrotic (necrosis > 50%), subendocardial necrotic (1–50% necrosis) and viable (necrosis = 0). The combination of the two latter groups is referred to as predominantly viable (0–50%).

Transmural necrotic sectors display thinning of the myocardial circumferential areas of left ventricular wall. Transmurality of the infarct was defined as the sum of the epicardial and endocardial infarct circumference divided by the sum of the total LV epicardial and endocardial circumferences using computer-based planimetry [29]. Fibrosis was measured by Masson’s Trichrome (MT) staining and expressed as percent of left ventricle in a segment. Hearts were washed three times in PBS at 4°C. Hearts were then cut into three transverse segments. Each segment was fixed in 10% para-formaldehyde and embedded in paraffin. The middle transverse segment was sectioned and stained with MT for both wall thickness (epi-to-endocardial distance) and fibrosis (blue stained collagen fibers) measurements. The mean left ventricle (LV) wall thickness, fibrosis and total LV area were measured from three equidistant points.

**Tissue Preparation for detection of eNOS, p-eNOS, iNOS TNF-α, IL-6 and IL-10**

To assess the effects of pGz on eNOS, p-eNOS and iNOS and inflammatory TNF-α, IL-6 and anti-inflammatory cytokine IL-10 protein levels were determined. Samples of the left ventricle were removed and immediately frozen in liquid nitrogen for Western Blot and cytokine protein chemiluminescent analysis. Care was taken to consistently harvest the same region of the left ventricle from all animals. Sections of the left ventricular myocardium were individually minced and homogenized at 4°C followed by one step total protein extraction with an Extraction Buffer System (Invitrogen Corporation, Carlsbad, CA) according to the manufacturer’s protocol. Homogenates were centrifuged at 4°C for 20 minutes at 12,000 rpm. The supernatant was decanted and assayed for total protein content. The extracted total cardiac tissue protein was measured by the BCA Protein Assay (Thermo Fisher Scientific, Waltham, MA) on a SpectraMax Plate Reader (Molecular Devices, Sunnyvale, CA). Individual proteins were then analyzed by Western Blot. Equal amounts of total protein were separated on 4–12% NuPAGE Novex Bis-Tris SDS-PAGE Gels (Invitrogen Corporation, Carlsbad, CA) and transferred to Immobilon-FL PVDF membrane (Millipore Corporation, Billerica, MA). The PVDF membrane was treated with a blocking agent (GE Healthcare Bio-Sciences Corporation) and probed with primary, fluorescein-linked secondary antibodies as well as anti-fluorescein alkaline phosphatase conjugate. Primary antibodies to eNOS, p-eNOS\(^{(\text{Ser1177})}\), iNOS, and GADPH (Glyceraldehyde-3-phosphate dehydrogenase) as an individual protein loading control (Santa Cruz Biotechnology, Inc. Santa Cruz, CA.) were employed. TNF-α, IL-6, IL-10 where determined using Rat Cytokine Kit (R&D Systems Inc., Minneapolis, MN). Equal amounts of protein 400 μg were used for analysis. Cytokine levels where normalized to Sham samples. Blots were visualized by Enhanced Chemiluminescence (ECF) (GE Healthcare Bio-Sciences Corporation, Piscatawy, NJ) on Storm 860 Imaging System (GE Healthcare Bio-Sciences Corporation, Piscatawy, NJ). The Storm 860 Imaging System exhibits a linear response to fluorescent signal intensities and protein levels were quantified using ImageQuant software (GE Healthcare Bio-Sciences Corporation, Piscatawy, NJ).
Data Analysis

Primary outcomes are survival and myocardial infarct size. Secondary outcomes are myocardial fibrosis, hemodynamics and protein expression. Myocardial contractility measurements were analyzed using a two-way analysis of variance with repeated measures. When appropriate, post hoc Fisher’s least significant difference test was carried out. Myocardial protein analysis parameters were subjected to analysis of variance with a Fisher’s least significant difference test used post hoc. Statistical significance was established at $p < 0.05$. Sample size was calculated using Statistica (StatSoft, Tulsa, OK) based on power analysis with $\alpha = 0.05$ and power 0.80. All data are expressed as Mean ± SD.

Results

Survival and Myocardial Infarct Size and Myocardial Fibrosis

All animals survived myocardial infarction without reperfusion at 24 hr. At 1 week post MI, 70% of the MI-CONT and 90% MI-pGz animals survived ($p < 0.01$). Four weeks after MI, 80% of the pGz treated animals survived and 50% of the MI-CONT ($p < 0.001$) (Fig. 2).

---

Fig 2. pGz Improves Survival After Myocardial Infarction. Kaplan-Meir Survival Curves. Survival during the four weeks after myocardial infarction in MI-pGz and MI-CONT groups. † $p < 0.01$.

doi:10.1371/journal.pone.0121069.g002
Infarct size prior to randomization was 38±4%. Treatment with pGz for four weeks decreased transmurality of the infarct from 60±5% for MI-CONT to 48±4% for MI-pGz (p<0.01). The ratio of left ventricular wall thickness to the MI thickness was significantly smaller in MI-CONT 0.9±0.5 compared to 3.1±0.7 for MI-pGz (p<0.01), additionally the amount of left ventricular collagen was 35±4% in MI-CONT compared to 22±4% in pGz treated animals (p<0.01)(Fig. 3).

**Hemodynamics and Myocardial Performance**

Ejection fraction and Fractional shortening significantly decreased at 1, 3, and four weeks after MI in both MI-CONT and MI-pGz compared to the immediate post MI time period. Over the four week post MI period, EF decreased an average of 35% from immediate post MI values in MI-pGz, while in MI-CONT the average decrease was 53%. Similarly FS, decreased on average 46% in MI-pGz, and 56% in MI-CONT (p<0.01) (Fig. 4).

As expected and in agreement with other studies, MI significantly decreased invasive measures of afterload, preload, integrated myocardial performance, and contractility [30, 31]. Four weeks of pGz significantly improved left ventricular end systolic pressure (LVESP) and invasive contractility measures, including; dp/dt, end systolic and end diastolic pressure volume relation (ESPVR, EDPVR), and significantly improved LVEDP, compared to MI-CONT. (Table 1, Fig. 5).

**Protein expression of eNOS, p-eNOS, iNOS, TNF-α, IL-6 and IL-10**

Compared to sham animals four weeks after myocardial infarction, there was a significant decrease in left ventricular protein content of eNOS (66%), p-eNOS(55%), and a significant increase in iNOS (100%), pGz after MI significantly increased eNOS (78%), p-eNOS (56%) and abrogated the increase in iNOS to only 20% compared with MI-CONT(Fig. 6).

pGz after MI decreased left ventricular protein content of IL-6 and TNF-α to 33% and 25% respectively of MI-CONT (p<0.01). pGz also significantly increased the anti-inflammatory signaling cytokine IL-10, 100% of MI-CONT (p<0.01). Additionally, the ratio of IL-10/ TNF-α was also significantly increased 1.1±0.05 vs. 0.4±0.05 in MI-pGz vs. MI-CONT (p<0.01) (Fig. 6.).

**Discussion**

Our study assessed the beneficial functional effects of treatment with pGz after experimental MI in rats. pGz administered one hour daily significantly improved survival and myocardial function. It decreased myocardial fibrosis and transmurality of the infarct, associated with increased eNOS, p-eNOS, and IL-10 along with decreased expression of TNF-α, IL-6 and iNOS.

**pGz Improves Survival and Hemodynamics**

pGz improved survival and contractile performance in this post MI model of heart failure. pGz has been shown to increase myocardial p-eNOS and NO and induce genomic up regulation of eNOS. The present study shows that daily pGz after MI significantly increases eNOS and p-eNOS, while significantly decreasing iNOS expression. Additionally pGz has also been shown to increase myocardial nNOS [10, 13, 32, 33]. The role of NO in cardioprotection and as a therapeutic modality in myocardial repair and remodeling, has been extensively reviewed by other investigators with both eNOS and nNOS playing a significant role in lessening injury, reducing apoptosis, decreasing myocardial fibrosis and ameliorating injury mediated by both reactive oxygen (ROS) and nitrogen oxide species (RNS) [34, 35]. Pharmacologic enhancement of
Fig 3. pGz Reduced Infarct Size, Transmurality and Fibrosis. A. The ratio of left ventricular wall to myocardial infarct length in MI-CONT and MI-pGz, with representative microscopic findings. †p < 0.01 MI-CONT vs. MI-pGz. B. Left Ventricular Collagen as a % of the left ventricle in MI-CONT and MI-pGz, with representative microscopic findings. Blue staining denotes fibrosis †p < 0.01 MI-CONT vs. MI-pGz.

doi:10.1371/journal.pone.0121069.g003
eNOS and nNOS has also been shown to be cardioprotective after MI in mice [36] and enhancing mesenchymal cell therapy in swine [37]. The role of iNOS in myocardial repair and remodeling is less clear and controversial; with studies suggesting that increased NO production thru overexpression of iNOS contributes to detrimental cardiac remodeling in heart failure, [38–40] and lack of iNOS improving cardiac reserve post MI [41]. In contrast others showed a protective role for iNOS in LV remodeling in a cardiomyopathy hamster heart model [42]. Recently, potentiation of NO signaling through inhibition of phosphodiesterase 5 (PDE5) has shown effectiveness in preventing cardiac hypertrophy and heart failure induced by pressure overload in animal models as well as, promising for human heart failure, diabetic cardiomyopathy, and pulmonary hypertension [43].

pGz Treatment Decreases Myocardial Fibrosis

Daily pGz treatment commencing 24 hr. after ischemia for four weeks improved the amount of viable left ventricle as evidenced by a higher ratio of left ventricular wall thickness to myocardial infarct thickness, and lower transmural extension of the infarct. Additionally, left ventricular collagen content, a measure of myocardial fibrosis, was reduced by 37% in pGz treated animals. The latter was associated with a decrease in pro-inflammatory cytokines, and increase in anti-inflammatory signaling cytokine.

Cytokines and chemokines have been shown to be important signaling molecules for early fibrosis [44–49]. In our model of MI, TNF-α and IL-6 measures of pro-inflammation were

Table 1. Invasive Hemodynamic Measures of Myocardial Function.

|                      | Sham       | MI-CONT    | MI-pGz     |
|----------------------|------------|------------|------------|
| Heart Rate (bpm)     | 322(15)    | 348(20)    | 351(11)    |
| **Integrated Performance** |           |            |            |
| EF(%)                | 67(1)      | 35(3.4)*   | 48(1.3)**†|
| SW (mmHgxμl)         | 9959(288)  | 8342(472)* | 8478(380)* |
| **Afterload**        |            |            |            |
| LVESP(mmHg)          | 149(3)     | 133(2.5) * | 140(1.4)**†|
| **Preload**          |            |            |            |
| LVEDP(mmHg)          | 9(1)       | 22(6)*     | 11(3)†     |
| **Contractility**    |            |            |            |
| dP/dtmax (mmHg/s)    | 13,593(228)| 7,742(225)*| 11,916(14) *†|
| ESPVR (mmHgxμl)      | 2.64 (0.19)| 1.08(0.06)*| 1.58(0.16) *†|
| EDPVR (mmHgxμl)      | 0.041(0.003)| 0.083(0.004)*| 0.063(0.011) *†|

Invasive hemodynamic measures obtained from the analysis if the pressure volume relationship of myocardial function at four weeks after myocardial infarction in Sham, MI-CONT and MI-pGz. Ejection Fraction (EF%), Stroke work (SW), Left Ventricular End Systolic Pressure (LVESP), Left Ventricular End Diastolic Pressure (LVEDP), End Systolic Pressure Volume Relationship (ESPVR), and End Diastolic Pressure Volume Relationship (EDPVR).

* p < 0.01 MI-CONT and MI-pGz vs. Sham.
†p < 0.01 MI-CONT vs. MI-pGz.
reduced in pGz treated animals while IL-10 an anti-inflammatory signaling cytokine was increased in pGz treated animals. Additionally, the balance of IL-10/ TNF-α in pGz treated animals was shifted to the more favorable anti-inflammatory ratio. Other investigators have also shown that both exercise and statins may also shift this ratio [50, 51].

During myocardial ischemia, TNF-α is released from macrophages, monocytes and mast cells and after reperfusion TNF-α is expressed and secreted in both cardiomyocytes and fibroblasts[52]. TNF-α has an ambivalent role in MI depending on the receptor subtype that is activated. Cell signaling through TNFR1 exacerbates remodeling, hypertrophy and apoptosis in heart failure, whereas TNFR2 has opposite effects [53].

Physical exercise decreases symptoms of coronary heart disease and is at the core of cardiac rehabilitation [54, 55]. Exercise as a method ameliorating ventricular remodeling after MI has been reported in various animal models including rats [50, 56], and humans [57, 58]. In rats and pigs, we previously showed that a single hour of pGz induces upregulation and activation of nNOS, eNOS and Akt and their respective phosphorylated proteins in the heart within 4 hr. of exposure [8, 10]. In the current study, pGz after MI also increased eNOS protein expression and phosphorylation.

Fig 5. Invasive Pressure Volume Relationship. Representative loops for the pressure volume relationship of the left ventricle four weeks after myocardial infarction determined at baseline, and after reduction of preload via occlusion in Sham, MI-CONT and MI-pGz.

doi:10.1371/journal.pone.0121069.g005
Fig 6. pGz Increases eNOS Signaling and IL-10 Expression, whereas it Reduces iNOS, TNF-α and IL-6 Expression.

A. Left ventricular protein content of endothelial derived nitric oxide synthase (eNOS) and phosphorylated eNOS (p-eNOS) as well as inducible nitric oxide synthase (iNOS), for Sham, MI-CONT and MI-pGz with representative immune blots for each group. * p < 0.01 MI-CONT and MI-pGz vs. Sham.
Taken together our findings suggest that pGz post MI improves myocardial function, decreases inflammatory signaling, and modifies myocardial remodeling. It is plausible that these changes are at least in part mediated via pGz-induced eNOS up regulation and modulation of an inflammatory phenotype [35, 59–61].

How Does pGz Improve Survival and Contractile Performance

Several lines of evidence suggest that intracellular Ca\(^{2+}\) ([Ca\(^{2+}\)]\(_{i}\)) and Na\(^{+}\) ([Na\(^{+}\)]\(_{i}\)) overload are prime causes of myocardial injury and death during MI [62, 63]. An excessive increase of intracellular Ca\(^{2+}\) causes mitochondrial dysfunction, reduces adenosine triphosphate (ATP) production [64, 65], and activates Ca\(^{2+}\)-dependent protease [66], all of which contribute to impairment of the [Ca\(^{2+}\)]\(_{i}\) homeostasis. In addition, there is an important interplay between [Na\(^{+}\)]\(_{i}\) and Ca\(^{2+}\) handling, so that altered levels of [Na\(^{+}\)]\(_{i}\) and Na\(^{+}\) transporters can have profound effects on both contractile function and arrhythmogenesis [67, 68]. An increase in [Na\(^{+}\)]\(_{i}\) activates the Na\(^{+}\)/Ca\(^{2+}\) exchanger in its reverse mode (Ca\(^{2+}\) in/Na\(^{+}\) out) which in turn further elevates [Ca\(^{2+}\)]\(_{i}\) [69] whereas activation of Na\(^{+}\)/H\(^{+}\) exchanger induces acidification of intracellular medium [70]. Thus, both [Ca\(^{2+}\)]\(_{i}\) and intracellular pH (pHi) in cardiac myocytes depend strongly on [Na\(^{+}\)]\(_{i}\).

Using an *in vitro* model of hypoxia and reoxygenation, we showed that pGz partially prevented intracellular Ca\(^{2+}\) and Na\(^{+}\) overload and acidification of the intracellular medium during hypoxia and reoxygenation [71]. This favorable effect regarding [Ca\(^{2+}\)]\(_{i}\) and [Na\(^{+}\)]\(_{i}\) concentrations by pGz may be explained on the basis of the multiple effects of NO as a cardioprotective molecule [72–78]. These beneficial effects induced by pGz appear to be mediated by increased production of NO since pretreatment with L-NAME, an inhibitor of nitric oxide synthase blocks the pGz effect on intracellular [Ca\(^{2+}\)]\(_{i}\), [Na\(^{+}\)]\(_{i}\) and pH. Normalization of Ca\(^{2+}\) homeostasis in salvageable cardiomyocytes might also reduce cell death by necrosis and apoptosis, decreasing the infarct size and reducing remodeling [79].

Limitations to the present study must be acknowledged. pGz increases serum prostaglandins and adrenomedullin as well as myocardial nNOS, all which are cardioprotective [6, 8, 10, 14, 80–82]. The aforementioned were not analyzed in the current study. Additionally, we have not directly measured NO levels in this model. Notwithstanding these limitations, our data demonstrate that pGz applied after MI improves myocardial function, and favorably diminishes adverse myocardial remodeling after MI. These data are in agreement with early human data, which showed that pGz after chronic MI, improved exercise capacity, and left ventricular function and increased coronary flow reserve [83, 84].

Conclusions

The present study demonstrates that a non-pharmacologic, non-invasive intervention which increases pulsatile shear stress to the vascular endothelium, can protect the heart after MI. There are significant clinical applications to the pGz stimulus. In addition to being a preconditioning stimulus, pGz may serve as a simple therapeutic modality to improve myocardial function after MI. pGz is particularly suited for individuals who cannot or will not exercise due to physical or mental limitations. Since, pGz has been shown to be safe in healthy and diseased...
human individuals and unlike exercise does not require subject cooperation, translation of its use in humans post MI warrants clinical investigation [7, 84, 85].

Supporting Information

S1 Table. Modified Assessment Scoring Criteria and Acute Pain Assessment for rat survival surgery and post-operative care.

(PDF)

Acknowledgments

The authors gratefully acknowledge the editorial contribution of Dr. Marvin Sackner.

Author Contributions

Conceived and designed the experiments: AU JB PK FA JRL JAA. Performed the experiments: AU JB. Analyzed the data: AU JAA. Contributed reagents/materials/analysis tools: AU JB PK FA JRL JAA. Wrote the paper: AU PK FA JRL JAA.

References

1. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, et al. Heart disease and stroke statistics—2014 update: a report from the American Heart Association. Circulation. 2014; 129(3):e28–e292. doi:10.1161/01.cir.0000441139.02102.80 PMID: 24352519

2. Seferovic PM, Stoerk S, Filippatos G, Mareev V, Kavoliuniene A, Ristic AD, et al. Organization of heart failure management in European Society of Cardiology member countries: survey of the Heart Failure Association of the European Society of Cardiology in collaboration with the Heart Failure National Societies/Working Groups. Eur J Heart Fail. 2013; 15(9):947–59. doi:10.1093/eurjhf/hft092 PMID: 23787723

3. Guha K, McDonagh T. Heart failure epidemiology: European perspective. Current cardiology reviews. 2013; 9(2):123–7. PMID:23597298

4. Heidenreich PA, Albert NM, Allen LA, Bluemke DA, Butler J, Fonarow GC, et al. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circulation heart failure. 2013; 6(3):606–19. doi: 10.1161/HFAC.0b013e318231329a PMID: 23616602

5. Adams JA, Mangino MJ, Bassuk J, Kurlansky P, Sackner MA. Regional blood flow during periodic acceleration. Critical care medicine. 2001; 29(10):1983–8. PMID: 11588467

6. Adams JA, Bassuk J, Wu D, Grana M, Kurlansky P, Sackner MA. Periodic acceleration: effects on vasoactive, fibrinolytic, and coagulation factors. J Appl Physiol. 2005; 98(3):1083–90. PMID:15501928

7. Sackner MA, Gummels E, Adams JA. Effect of moderate-intensity exercise, whole-body periodic acceleration, and passive cycling on nitric oxide release into circulation. Chest. 2005; 128(4):2794–803. PMID: 16236957

8. Uryash A, Wu H, Bassuk J, Kurlansky P, Adams JA. Periodic acceleration (pGz) acutely increases endothelial and neuronal nitric oxide synthase expression in endomyocardium of normal swine. Peptides. 2009; 30(2):373–7. doi: 10.1016/j.peptides.2008.10.014 PMID: 19022311

9. Adams JA, Moore JJE, Moreno MR, Coelho J, Bassuk J, Wu D. Effects of Periodic Body Acceleration on the In Vivo Vasoactive Response to N-w-nitro-L-arginine and the In Vitro Nitric Oxide Production. Annals of biomedical engineering. 2003; 31(11):1337–46. PMID: 14758924

10. Wu H, Jin Y, Arias J, Bassuk J, Uryash A, Kurlansky P, et al. In vivo upregulation of nitric oxide synthases in healthy rats. Nitric Oxide. 2009; 21(1):63–8. doi: 10.1016/j.niox.2009.05.004 PMID: 19481168

11. Hutcheson IR, Griffith TM. Release of endothelium-derived relaxing factor is modulated both by frequency and amplitude of pulsatile flow. Am J Physiol. 1991; 261(1 Pt 2):H257–62. PMID: 1858928

12. Li Y, Zheng J, Bird IM, Magnness RR. Effects of pulsatile shear stress on signaling mechanisms controlling nitric oxide production, endothelial nitric oxide synthase phosphorylation, and expression in ovine fetoplacental artery endothelial cells. Endothelium. 2005; 12(1–2):21–39. PMID: 16410226

13. Uryash A, Wu H, Bassuk J, Kurlansky P, Sackner MA, Adams JA. Low-amplitude pulses to the circulation through periodic acceleration induces endothelial-dependent vasodilatation. J Appl Physiol (1985). 2009; 106(6):1840–7.
14. Martinez A, Arias J, Bassuk JA, Wu H, Kurlansky P, Adams JA. Adrenomedullin is increased by pulsatile shear stress on the vascular endothelium via periodic acceleration (pGz). Peptides. 2008; 29(1):73–8. PMID: 18054815
15. Committee on Recognition and Alleviation of Pain in Laboratory Animals NRC. Recognition and Alleviation of Pain in Laboratory Animals. Washington, D.C.: The National Academies Press; 2009.
16. Kohn FD. T.E. M. Guidelines for the Assessment and Management of Pain in Rodents and Rabbits. Available: http://www.aclam.org/Content/files/files/Public/Active/position_pain-rodent-rabbit.pdf Accessed 2015 Feb 15.
17. Carstens E. P.G M. Recognizing Pain and Distress in Laboratory Animals. ILAR journal / National Research Council, Institute of Laboratory Animal Resources. 2000; 41(2):62–71. PMID: 11304586
18. Aarsaether E, Rosner A, Straumbotn E, Busund R. Peak longitudinal strain most accurately reflects myocardial segmental viability following acute myocardial infarction—an experimental study in open-chest pigs. Cardiovascular ultrasound. 2012; 10:23. doi: 10.1186/1476-7120-10-23 PMID: 22642798
19. Thibault H, Gomez L, Donal E, Pontier G, Scherrer-Crosbie M, Ovize M, et al. Acute myocardial infarction in mice: assessment of transmurality by strain rate imaging. American journal of physiology, 2007; 293(1):H496–502. PMID: 17384134
20. Lang R, Bierig M, Devereux R, Flachskampf F, Foster E, Pellikka P, et al. Recommendations for Chamber Quantification: A Report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, Developed in Conjunction with the European Association of Echocardiography, a Branch of the European Society of Cardiology. Journal of the American Society of Echocardiography. 2005; 18(12):1440–63. PMID: 16376782
21. American Veterinary Medical Association website. Available: https://www.avma.org/KB/Policies/Documents/euthanasia.pdf Accessed 2015 Feb 15.
22. Nemzek JA, Xiao HY, Minard AE, Bolgos GL, Remick DG. Humane endpoints in shock research. Shock. 2004; 21(1):17–25. PMID: 14676679
23. Toth LA. Defining the Moribund Condition as an Experimental Endpoint for Animal Research. ILAR journal / National Research Council, Institute of Laboratory Animal Resources. 2000; 41(2):72–9. PMID: 11406700
24. Morton BD. A Systematic Approach for Establishing Humane Endpoints. ILAR journal / National Research Council, Institute of Laboratory Animal Resources. 2000; 41(2):80–6. PMID: 11406701
25. McElroy CL, Gissen SA, Fishbein MC. Exercise-induced reduction in myocardial infarct size after coronary artery occlusion in the rat. Circulation. 1978; 57(5):958–62. PMID: 639217
26. Jain M, DerSimonian H, Brenner DA, Ngoy S, Teller P, Edge AS, et al. Cell therapy attenuates deleterious ventricular remodeling and improves cardiac performance after myocardial infarction. Circulation. 2001; 103(14):1920–7. PMID: 11294813
27. Gao F, Gao E, Yue TL, Ohlstein EH, Lopez BL, Christopher TA, et al. Nitric oxide mediates the antiapoptotic effect of insulin in myocardial ischemia-reperfusion: the roles of PI3-kinase, Akt, and endothelial nitric oxide synthase phosphorylation. Circulation. 2002; 105(12):1497–502. PMID: 11914261
28. Kamihata H, Matsubara H, Nishiue T, Fujiyama S, Tsutsumi Y, Ozono R, et al. Implantation of bone marrow mononuclear cells into ischemic myocardium enhances collateral perfusion and regional function via side supply of angioblasts, angiogenic ligands, and cytokines. Circulation. 2001; 104(9):1046–52. PMID: 11524400
29. Khan M, Kutala VK, Vikram DS, Wisel S, Chacko SM, Kuppusamy ML, et al. Skeletal myoblasts transplanted in the ischemic myocardium enhance in situ oxygenation and recovery of contractile function. American journal of physiology. 2007; 293(4):H2129–39. PMID: 17660391
30. Yoshida H, Takahashi M, Koshimizu M, T anonaka K, Oikawa R, Toyo-oka T, et al. Decrease in sarcoglycans and dystrophin in failing heart following acute myocardial infarction. Cardiovascular research. 2003; 59(2):419–27. PMID: 12909325
31. Stefanon I, Valero-Munoz M, Fernandes AA, Ribeiro RF Jr., Rodriguez C, Miana M, et al. Left and right ventricle late remodeling following myocardial infarction in rats. PLoS One. 2013; 8(5):e64986. doi: 10.1371/journal.pone.0064986 PMID: 23741440
32. Adams JA, Wu H, Bassuk JA, Arias J, Uryash A, Jorapur V, et al. Periodic acceleration (pGz) prior to whole body ischemia reperfusion injury provides early cardioprotective preconditioning. Life Sci. 2010; 86(19–20):707–15.
33. Uryash A, Wu H, Bassuk J, Kurlansky P, Adams JA. Preconditioning with periodic acceleration (pGz) provides second window of cardioprotection. Life sciences. 2012; 91(5–6):178–85.
34. Espey MG, Miranda KM, Thomas DD, Xavier S, Citrin D, Vitek MP, et al. A chemical perspective on the interplay between NO, reactive oxygen species, and reactive nitrogen oxide species. Annals of the New York Academy of Sciences. 2002; 962:195–206. PMID: 12076975
35. Otani H. The role of nitric oxide in myocardial repair and remodeling. Antioxid Redox Signal. 2009; 11 (8):1913–28. doi: 10.1089/ARS.2009.2453 PMID: 19203224

36. Aragon JP, Condit ME, Bhushan S, Predmore BL, Patel SS, Grinsfelder DB, et al. Beta3-adrenoceptor stimulation ameliorates myocardial ischemia-reperfusion injury via endothelial nitric oxide synthase and neuronal nitric oxide synthase activation. Journal of the American College of Cardiology. 2011; 58 (25):2683–91. doi: 10.1016/j.jacc.2011.09.033 PMID: 22152956

37. Song L, Yang YJ, Dong QT, Qian HY, Gao RL, Qiao SB, et al. Atorvastatin Enhance Efficacy of Mesenchymal Stem Cells Treatment for Swine Myocardial Infarction via Activation of Nitric Oxide Synthase. PLoS One. 2013; 8(5):e55477. doi: 10.1371/journal.pone.0055477 PMID: 23405158

38. Gilson WD, Epstein FH, Yang Z, Xu Y, Prasad KM, Toufektsian MC, et al. Borderzone contractile dysfunction is transiently attenuated and left ventricular structural remodeling is markedly reduced following reperfused myocardial infarction in inducible nitric oxide synthase knockout mice. Journal of the American College of Cardiology. 2007; 50(18):1799–807. PMID: 17964046

39. Haywood GA, Tsao PS, von der Leyen HE, Mann MJ, Keeling PJ, Trindade PT, et al. Expression of inducible nitric oxide synthase in human heart failure. Circulation. 1996; 93(6):1087–94. PMID: 8653828

40. Horinaka S, Kobayashi N, Mori Y, Yagi H, Onoda M, Matsuoka H. Expression of inducible nitric oxide synthase, left ventricular function and remodeling in Dahl salt-sensitive hypertensive rats. International journal of cardiology. 2003; 91(1):25–35. PMID: 12957726

41. Liu YH, Carretero OA, Cingolani OH, Liao TD, Sun Y, Xu J, et al. Role of inducible nitric oxide synthase in cardiac function and remodeling in mice with heart failure due to myocardial infarction. American journal of physiology. 2005; 289(6):H2616–23. PMID: 16055518

42. Matsuhashi S, Otani H, Okazaki T, Yamashita K, Akita Y, Sato D, et al. N-acetylcysteine abolishes the protective effect of losartan against left ventricular remodeling in cardiomyopathy hamster. Antioxid Redox Signal. 2008; 10(12):1999–2008. doi: 10.1089/ars.2008.2069 PMID: 18665799

43. van Berlo JH, Maillet M, Molkentin JD. Signaling effectors underlying pathologic growth and remodeling of the heart. The Journal of clinical investigation. 2013; 123(1):37–45. doi: 10.1172/JCI62839 PMID: 23281408

44. Hemalatha T, Balachandran C, Manohar BM, Nayeem M, Subramaniam S, Sharma HS, et al. Myocardial expression of PDECGF is associated with extracellular matrix remodeling in experimental myocardial infarction in rats. Biochemistry and cell biology = Biochimie et biologie cellulaire. 2010; 88(3):491–503. doi: 10.1139/o09-165 PMID: 20555391

45. Ramani R, Mathier M, Wang P, Gibson G, Togel S, Dawson J, et al. Inhibition of tumor necrosis factor receptor-1-mediated pathways has beneficial effects in a murine model of postischememic remodeling. American journal of physiology. 2004; 287(3):H1369–77. PMID: 15317681

46. Trescher K, Bemecker O, Fellner B, Gyongyosi M, Schafer R, Aharinejad S, et al. Inflammation and postinfarct remodeling: overexpression of IkappaB prevents ventricular dilation via increasing TIMP levels. Cardiovascular research. 2006; 69(3):746–54. PMID: 16388787

47. Tian H, Huang ML, Liu KY, Jia ZB, Sun L, Jiang SL, et al. Inhibiting matrix metalloproteinase by cell-based timp-3 gene transfer effectively treats acute and chronic ischemic cardiomyopathy. Cell transplantation. 2012; 21(5):1039–53. doi: 10.3727/096368911X601000 PMID: 21944319

48. Nilsson L, Szymanski A, Swahn E, Jonasson L. Soluble TNF receptors are associated with infarct size and ventricular dysfunction in ST-elevation myocardial infarction. PLoS One. 2013; 8(2):e55477. doi: 10.1371/journal.pone.0055477 PMID: 23778495

49. Taha FJ, Alves JP, Kessler LP, Dal Lago P. Aerobic exercise improves the inflammatory profile correlated with cardiac remodeling and function in chronic heart failure rats. Clinics. 2013; 68(6):876–82. doi: 10.6061/clinics/2013(06)24 PMID: 23778495
Cardiology; the Councils on Cardiovascular Nursing, Epidemiology and Prevention, and Nutrition, Physical Activity, and Metabolism; and the American Association of Cardiovascular and Pulmonary Rehabilitation. Circulation. 2007; 115(20):2675–82. PMID: 17513578
55. Crisafulli A, Melis F, Tocco F, Santoboni UM, Lai C, Angiyo G, et al. Exercise-induced and nitroglycerin-induced myocardial preconditioning improves hemodynamics in patients with angina. American journal of physiology. 2004; 287(1):H235–42. PMID: 15016635
56. Kraljevic J, Marinovic J, Pravdic D, Zubin P, Dujic Z, Wisloff U, et al. Aerobic interval training attenuates remodelling and mitochondrial dysfunction in the post-infarction failing rat heart. Cardiovascular research. 2013; 99(1):55–64. doi: 10.1177/0020719713483863 PMID: 23168668
57. Giullaia F, Acampa W, Ricci F, Vitelli A, Maresca L, Mancini M, et al. Effects of exercise training started within 2 weeks after acute myocardial infarction on myocardial perfusion and left ventricular function: a gated SPECT imaging study. European journal of preventive cardiology. 2012; 19(6):1410–9. doi: 10.1177/1744806712447560 PMID: 22965517
58. Haykowsky M, Scott J, Esch B, Schopflocher D, Myers J, Paterson I, et al. A meta-analysis of the effects of exercise training on left ventricular remodelling following myocardial infarction: start early and go longer for greatest exercise benefits on remodeling. Trials. 2011; 12:92. doi: 10.1186/1745-6215-12-92 PMID: 21463531
59. Kolluru GK, Siamwala JH, Chatterjee S. eNOS phosphorylation in health and disease. Biochimie. 2010; 92(9):1186–98. doi: 10.1016/j.biochi.2010.03.020 PMID: 20363286
60. Judgutt BI. Nitric oxide and cardioprotection during ischemia-reperfusion. Heart Fail Rev. 2002; 7(4):391–405. PMID: 12379824
61. Judgutt BI. Nitric oxide and cardiovascular protection. Heart Fail Rev. 2003; 8(1):29–34.
62. Goldhaber JI, Phillipson KD. Cardiac sodium-calcium exchange and efficient excitation-contraction coupling: implications for heart disease. Adv Exp Med Biol. 2013; 961:355–64. doi: 10.1007/978-1-4614-4756-6_30 PMID: 23224984
63. Gomez AM, Guatimosim S, Dilly KW, Vassort G, Lederer WJ. Heart failure after myocardial infarction: altered excitation-contraction coupling. Circulation. 2001; 104(6):688–93. PMID: 11489776
64. Parr DR, Wimhurst JM, Harris EJ. Calcium-induced damage of rat heart mitochondria. Cardiovascular research. 1975; 9(3):366–72. PMID: 1175182
65. Ma HJ, Li Q, Ma HJ, Guan Y, Shi M, Yang J, et al. Chronic Intermittent Hypobaric Hypoxia Ameliorates Remodelling and Mitochondrial Dysfunction in the Post-infarction Failing Rat Heart. Cardiovascular research. 2013; 99(1):55–64. doi: 10.1093/cvr/cvt080 PMID: 23554460
66. Kishimoto A, Kajikawa N, Shiota M, Nishizuka Y. Proteolytic activation of calcium-activated, phospholipid-dependent protein kinase by calcium-dependent neutral protease. The Journal of biological chemistry. 1983; 258(2):1156–64. PMID: 6296071
67. Yao A, Su Z, Nonaka A, Zubair I, Spitzer KW, Bridge JH, et al. Abnormal myocyte Ca2+ homeostasis in rabbits with pacing-induced heart failure. Am J Physiol. 1998; 275(4 Pt 2):H1441–8. PMID: 9746495
68. Despa S, Bers DM. Na(+) transport in the normal and failing heart. Circ Res. 2004; 94(9):391–9. doi: 10.1161/01.RES.0000123426.20711.80 PMID: 15124982
69. Vaughan-Jones RD. Cross-talking Ca2+, H+ and nitric oxide. The Journal of physiology. 2014; 592(4):3177–8. doi: 10.1113/jphysiol.2013.278697 PMID: 25085973
70. Barouch LA, Harrison RW, Skaf MW, Rosas GO, Cappola TP, Kobeissi ZA, et al. Nitric oxide regulates the heart by spatial confinement of nitric oxide synthase isoforms. Nature. 2002; 416(6878):337–9. PMID: 11907582
71. Hare JM. Nitric oxide and excitation-contraction coupling. Journal of molecular and cellular cardiology. 2003; 35(7):719–29. PMID: 12618651
76. Lim G, Venetucci L, Eisner DA, Casadei B. Does nitric oxide modulate cardiac ryanodine receptor function? Implications for excitation-contraction coupling. Cardiovascular research. 2008; 77(2):256–64. PMID: 18006480

77. Pogwizd SM, Sipido KR, Verdonck F, Bers DM. Intracellular Na in animal models of hypertrophy and heart failure: contractile function and arrhythmogenesis. Cardiovascular research. 2003; 57(4):887–96. PMID: 12650867

78. Loga F, Domes K, Freichel M, Flockerzi V, Dietrich A, Birnbaumer L, et al. The role of cGMP/cGKI signalling and Trpc channels in regulation of vascular tone. Cardiovascular research. 2013; 100(2):280–7. doi:10.1093/cvr/cvt176 PMID: 23832809

79. Dorn GW 2nd. Apoptotic and non-apoptotic programmed cardiomyocyte death in ventricular remodeling. Cardiovascular research. 2009; 81(3):465–73. doi: 10.1093/cvr/cvn243 PMID: 18779231

80. Das DK, Maulik N. Cardiac genomic response following preconditioning stimulus. Cardiovascular research. 2006; 70(2):254–63. PMID: 16566910

81. Hamilton KL, Staib JL, Phillips T, Hess A, Lennon SL, Powers SK. Exercise, antioxidants, and HSP72: protection against myocardial ischemia/reperfusion. Free radical biology & medicine. 2003; 34(7):800–9.

82. Marini M, Lapalombella R, Margonato V, Ronchi R, Samaja M, Scapin C, et al. Mild exercise training, cardioprotection and stress genes profile. European Journal of Applied Physiology and Occupational Physiology. 2007; 99(5):503–10. PMID: 17206441

83. Miyamoto S, Fujita M, Inoko M, Oba M, Hosokawa R, Haruna T, et al. Effect on treadmill exercise capacity, myocardial ischemia, and left ventricular function as a result of repeated whole-body periodic acceleration with heparin pretreatment in patients with angina pectoris and mild left ventricular dysfunction. The American journal of cardiology. 2011; 107(2):168–74. doi: 10.1016/j.amjcard.2010.09.007 PMID: 21129712

84. Fukuda S, Shimada K, Kawasaki T, Kono Y, Jissho S, Taguchi H, et al. "Passive exercise" using whole body periodic acceleration: effects on coronary microcirculation. Am Heart J. 2010; 159(4):620–6. doi: 10.1016/j.ahj.2009.12.034 PMID: 20362721

85. Kohler M, Amann-Vesti BR, Clarenbach CF, Brack T, Noll G, Russi EW, et al. Periodic whole body acceleration: a novel therapy for cardiovascular disease. VASA Zeitschrift fur Gefasskrankheiten Journal for vascular diseases. 2007; 36(4):261–6.